HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

Name: HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization
Published: 2026
License: Public Domain

Mayo Clinic · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

metastatic colorectal carcinoma, metastatic malignant neoplasm in the liver, resectable colorectal carcinoma, stage iv colorectal cancer ajcc v8, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

Related documents